Lidemol

Each gram contains: Fluocinonide 500 mcg (in an emollient cream base).
The formulation does not contain lanolin, parabens or phenolic compounds.

Anti-inflammatory and Antipruritic.
Fluocinonide (Lidemol) 500 mcg/g (0.05%) Cream is primarily effective because of the anti-inflammatory, antipruritic and vasoconstrictor actions of Fluocinonide.

Fluocinonide (Lidemol) 500 mcg/g (0.05%) Cream is suitable for treating a wide variety of localized inflammatory, pruritic and allergic disorders of the skin and mucosa. It is indicated for topical application in the following conditions: Insect bite reactions, photodermatitis, psoriasis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, eczematous dermatitis, lichen planus, prurigo nodularis, pretibial myxedema, necrobiosis lipoidica, neurodermatitis, intertriginous psoriasis, nummular eczema, discoid lupus erythematosus, exfoliative dermatitis, pruritus ani et vulvae, lichen simplex chronicus, intertrigo, otitis externa and stasis dermatitis.

A small amount should be applied lightly to the affected skin two to three times daily with gentle but thorough massage. When the condition is under control, the dosage should be decreased gradually.

Fluocinonide (Lidemol) 500 mcg/g (0.05%) Cream is contraindicated in those patients with a history of hypersensitivity to any of its components.

Prolonged use of topical corticosteroid products may produce atrophy of the skin. When used on the face, this may occur even with short term use.
Significant systemic absorption may result when corticosteroids are applied over large areas of the body, even when occlusion is not used.
Administration of topical corticosteroids to children should be limited to a short period of time and to the smallest amount compatible with an effective therapeutic regimen.
These preparations are not intended for ophthalmic use.
Topical corticosteroids should be used with caution on lesions close to the eye.
Occlusive dressing increases the percutaneous absorption of topical corticosteroids. Its use can be helpful in the treatment of recalcitrant dermatoses. Tight-fitting diapers or plastic pants on a child may also function as an occlusive dressing and increase absorption of topical corticosteroids by the underlying skin.
Patients (particularly children) receiving a large dose of topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, the dose should be reduced or gradually discontinued.
In the presence of an infection, the use of an appropriate antibacterial, antiviral or antifungal agent should be instituted. If a favourable response does not occur promptly, Fluocinonide (Lidemol) 500 mcg/g (0.05%) Cream should be discontinued until the infection has been adequately controlled.
Use in Pregnancy: See USE IN PREGNANCY & LACTATION section for further information.

In laboratory animals, increases in incidences of fetal abnormalities have been associated with exposure of gestating females to topical corticosteroids, in some cases at rather low dosage levels.
While topical corticosteroids have not been reported to have an adverse effect on human pregnancy, the safety of their use in pregnant women has not been established absolutely. Therefore, drugs of this class should not be used extensively on pregnant patients, in large amounts or for prolonged periods of time, especially for the first three months of pregnancy.

The following local adverse reactions have been reported with topical corticosteroids: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

Store at temperatures not exceeding 30°C.

Topical Corticosteroids

D07AC08 - fluocinonide ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

Rx